XOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93

XOMA Co. (NASDAQ:XOMA) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $19.93 and traded as high as $24.62. XOMA shares last traded at $24.38, with a volume of 7,113 shares trading hands.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $74.00 price target on shares of XOMA in a research report on Friday, February 16th.

XOMA Stock Up 0.2 %

The stock has a 50-day simple moving average of $24.19 and a two-hundred day simple moving average of $19.93. The company has a quick ratio of 8.68, a current ratio of 8.68 and a debt-to-equity ratio of 1.34. The firm has a market cap of $283.78 million, a PE ratio of -6.03 and a beta of 0.58.

XOMA (NASDAQ:XOMA) last released its quarterly earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. The firm had revenue of $1.83 million for the quarter, compared to analysts’ expectations of $1.01 million. Analysts expect that XOMA Co. will post -1.73 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of XOMA. BlackRock Inc. grew its stake in shares of XOMA by 252.0% during the second quarter. BlackRock Inc. now owns 428,739 shares of the biotechnology company’s stock valued at $8,099,000 after buying an additional 306,944 shares during the last quarter. FMR LLC grew its stake in shares of XOMA by 20.4% during the second quarter. FMR LLC now owns 1,130,184 shares of the biotechnology company’s stock valued at $25,180,000 after buying an additional 191,703 shares during the last quarter. Stonepine Capital Management LLC grew its stake in shares of XOMA by 25.0% during the third quarter. Stonepine Capital Management LLC now owns 436,602 shares of the biotechnology company’s stock valued at $6,152,000 after buying an additional 87,203 shares during the last quarter. State Street Corp grew its stake in shares of XOMA by 216.3% during the second quarter. State Street Corp now owns 127,375 shares of the biotechnology company’s stock valued at $2,406,000 after buying an additional 87,101 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of XOMA by 88.4% in the second quarter. Geode Capital Management LLC now owns 153,895 shares of the biotechnology company’s stock worth $2,907,000 after purchasing an additional 72,223 shares during the last quarter. 95.92% of the stock is owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.